{"slug":"policy","tag":"policy","variants":["policy"],"description":"No description yet","count":11,"kinds":{"person":4,"term":3,"technology":4},"related":[{"slug":"rejuvenation","tag":"rejuvenation","shared":4},{"slug":"survivorship","tag":"survivorship","shared":4},{"slug":"psychosocial","tag":"psychosocial","shared":3},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":2},{"slug":"evidence","tag":"evidence","shared":1},{"slug":"exercise","tag":"exercise","shared":1},{"slug":"genetics","tag":"genetics","shared":1},{"slug":"global","tag":"global","shared":1},{"slug":"hta","tag":"hta","shared":1},{"slug":"instruments","tag":"instruments","shared":1},{"slug":"leadership","tag":"leadership","shared":1},{"slug":"lung","tag":"lung","shared":1}],"records":[{"id":"david-baldwin","kind":"person","name":"David Baldwin","route":"/people/david-baldwin/","tldr":"The Nottingham chest physician who chairs the UK clinical expert group for lung cancer and advises the National Screening Committee: the person whose job it is to turn the screening evidence into an NHS service."},{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","tldr":"Emergency physician who became Chief Executive of NICE, the body that appraises new cancer medicines and issues clinical guidance for the NHS, in December 2025."},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","tldr":"Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding."},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","tldr":"Oncologist who co-led CHALLENGE and founded Common Sense Oncology to refocus trials on outcomes that matter to patients."},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","tldr":"New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated."},{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","tldr":"There are not enough oncologists, radiation therapists, pathologists, oncology nurses and pharmacists for the growing number of patients, in rich countries and especially in poor ones; burnout, geography and training pipelines shape who receives care."},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","tldr":"The World Health Organization's list of medicines every health system should provide, which now includes about 60 cancer drugs from cyclophosphamide and cisplatin to trastuzumab, imatinib and PD-1 inhibitors, guiding procurement and pricing in lower-income countries."},{"id":"rejuv-life-employment-rights-uk","kind":"technology","name":"Employment rights with cancer in the United Kingdom","route":"/technologies/rejuv-life-employment-rights-uk/","status":"standard-of-care","tldr":"Schedule 1 of the Equality Act 2010 says in one sentence that \"Cancer, HIV infection and multiple sclerosis are each a disability\", so protection applies from the moment of diagnosis rather than when the illness starts to limit anything. That brings the employer's duty to make reasonable adjustments, and Statutory Sick Pay of £123.25 a week for up to 28 weeks."},{"id":"rejuv-life-employment-rights-us","kind":"technology","name":"Employment rights with cancer in the United States","route":"/technologies/rejuv-life-employment-rights-us/","status":"standard-of-care","tldr":"Federal regulation states that \"cancer substantially limits normal cell growth\", and the statute counts an impairment in remission if it would substantially limit a major life activity when active. The Americans with Disabilities Act reaches employers with 15 or more employees; unpaid job-protected leave under the Family and Medical Leave Act is 12 workweeks a year."},{"id":"rejuv-life-insurance-loans-and-the-right-to-be-forgotten","kind":"technology","name":"Insurance, mortgages and the right to be forgotten","route":"/technologies/rejuv-life-insurance-loans-and-the-right-to-be-forgotten/","status":"emerging","tldr":"Nine European Union countries have passed laws giving people who have had cancer the right not to declare it when applying for a loan or insurance after a set period, commonly five to ten years for adults and five for a cancer diagnosed young. Where the laws have been in force longest, acceptance rates are high and the strain on insurers is reported as minimal."},{"id":"rejuv-measure-epro-implementation","kind":"technology","name":"What has actually been implemented since those trials, and what has not","route":"/technologies/rejuv-measure-epro-implementation/","status":"emerging","tldr":"The trials finished years ago and most people being treated for cancer are still not asked their symptoms between appointments. The clearest thing that changed is a United States payment model that now requires practices to collect them."}]}